Skip to main content
PMC home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1994 Jan;7(1):1–13. doi: 10.1128/cmr.7.1.1

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

A K Field 1, K K Biron 1
PMCID: PMC358302  PMID: 8118786

Abstract

In the past 4 years, interest in drug-resistant herpesviruses has evolved from the realm of academic laboratory studies to that of great clinical importance. Recurrent and persistent infections due to the herpes simplex viruses, varicella-zoster virus, and human cytomegalovirus have been an unwelcome consequence of immunosuppression in graft recipients, cancer patients, and those suffering from AIDS. Treatment of these infections with the available antiviral drugs, such as acyclovir, ganciclovir, and foscarnet, has resulted in both clinical benefit and the emergence of drug-resistant variants. In addition, the role of Epstein-Barr virus is being clarified for an array of disease syndromes, and therapeutic approaches are beginning to emerge. In the present review, the emergence and clinical importance of drug resistance among the herpesviruses have been explored. Furthermore, particular attention has been focused on our understanding of the mechanisms of drug resistance and how that understanding will guide us in the development of more effective antiviral drugs and drug usage.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acheson D. W., Leen C. L., Tariq W. U., Mandal B. K. Severe and recurrent varicella-zoster virus infection in a patient with the acquired immune deficiency syndrome. J Infect. 1988 Mar;16(2):193–197. doi: 10.1016/s0163-4453(88)94122-9. [DOI] [PubMed] [Google Scholar]
  2. Alessi E., Cusini M., Zerboni R., Cavicchini S., Uberti-Foppa C., Galli M., Moroni M. Unusual varicella zoster virus infection in patients with the acquired immunodeficiency syndrome. Arch Dermatol. 1988 Jul;124(7):1011–1013. [PubMed] [Google Scholar]
  3. Balfour H. H., Jr, Chace B. A., Stapleton J. T., Simmons R. L., Fryd D. S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989 May 25;320(21):1381–1387. doi: 10.1056/NEJM198905253202105. [DOI] [PubMed] [Google Scholar]
  4. Balfour H. H., Jr, Drew W. L., Hardy W. D., Heinemann M. H., Polsky B. Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. J Acquir Immune Defic Syndr. 1992;5 (Suppl 1):S37–S44. [PubMed] [Google Scholar]
  5. Balfour H. H., Jr Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am J Med. 1988 Aug 29;85(2A):68–73. [PubMed] [Google Scholar]
  6. Balfour H. H., Jr Varicella-zoster virus infections in the immunocompromised host. Natural history and treatment. Scand J Infect Dis Suppl. 1991;80:69–74. [PubMed] [Google Scholar]
  7. Barry D. W., Nusinoff-Lehrman S., Ellis M. N., Biron K. K., Furman P. A. Viral resistance, clinical experience. Scand J Infect Dis Suppl. 1985;47:155–164. [PubMed] [Google Scholar]
  8. Biron K. K., Fyfe J. A., Noblin J. E., Elion G. B. Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus. Am J Med. 1982 Jul 20;73(1A):383–386. doi: 10.1016/0002-9343(82)90128-0. [DOI] [PubMed] [Google Scholar]
  9. Biron K. K., Fyfe J. A., Stanat S. C., Leslie L. K., Sorrell J. B., Lambe C. U., Coen D. M. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8769–8773. doi: 10.1073/pnas.83.22.8769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Biron K. K., Stanat S. C., Sorrell J. B., Fyfe J. A., Keller P. M., Lambe C. U., Nelson D. J. Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2473–2477. doi: 10.1073/pnas.82.8.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Boivin G., Erice A., Crane D. D., Dunn D. L., Balfour H. H., Jr Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother. 1993 Feb;37(2):357–359. doi: 10.1128/aac.37.2.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chatis P. A., Crumpacker C. S. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology. 1991 Feb;180(2):793–797. doi: 10.1016/0042-6822(91)90093-q. [DOI] [PubMed] [Google Scholar]
  13. Chatis P. A., Crumpacker C. S. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother. 1992 Aug;36(8):1589–1595. doi: 10.1128/aac.36.8.1589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chatis P. A., Miller C. H., Schrager L. E., Crumpacker C. S. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):297–300. doi: 10.1056/NEJM198902023200507. [DOI] [PubMed] [Google Scholar]
  15. Chee M. S., Lawrence G. L., Barrell B. G. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J Gen Virol. 1989 May;70(Pt 5):1151–1160. doi: 10.1099/0022-1317-70-5-1151. [DOI] [PubMed] [Google Scholar]
  16. Chou S. W. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis. 1989 Jul;160(1):11–15. doi: 10.1093/infdis/160.1.11. [DOI] [PubMed] [Google Scholar]
  17. Chrisp P., Clissold S. P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 1991 Jan;41(1):104–129. doi: 10.2165/00003495-199141010-00009. [DOI] [PubMed] [Google Scholar]
  18. Coen D. M. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res. 1991 May;15(4):287–300. doi: 10.1016/0166-3542(91)90010-o. [DOI] [PubMed] [Google Scholar]
  19. Cohen P. R., Beltrani V. P., Grossman M. E. Disseminated herpes zoster in patients with human immunodeficiency virus infection. Am J Med. 1988 Jun;84(6):1076–1080. doi: 10.1016/0002-9343(88)90315-4. [DOI] [PubMed] [Google Scholar]
  20. Cohen P. R., Grossman M. E. Clinical features of human immunodeficiency virus-associated disseminated herpes zoster virus infection--a review of the literature. Clin Exp Dermatol. 1989 Jul;14(4):273–276. doi: 10.1111/j.1365-2230.1989.tb01978.x. [DOI] [PubMed] [Google Scholar]
  21. Cole N. L., Balfour H. H., Jr In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis. 1987 Mar;6(3):255–261. doi: 10.1016/0732-8893(87)90020-4. [DOI] [PubMed] [Google Scholar]
  22. Collins P., Larder B. A., Oliver N. M., Kemp S., Smith I. W., Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol. 1989 Feb;70(Pt 2):375–382. doi: 10.1099/0022-1317-70-2-375. [DOI] [PubMed] [Google Scholar]
  23. Crumpacker C. S., Schnipper L. E., Marlowe S. I., Kowalsky P. N., Hershey B. J., Levin M. J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982 Feb 11;306(6):343–346. doi: 10.1056/NEJM198202113060606. [DOI] [PubMed] [Google Scholar]
  24. D'Aquila R. T., Summers W. C. Isolation and characterization of phosphonoacetic acid-resistant mutants of human cytomegalovirus. J Virol. 1987 Apr;61(4):1291–1295. doi: 10.1128/jvi.61.4.1291-1295.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R. C., Croce C. M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824–7827. doi: 10.1073/pnas.79.24.7824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Darby G., Field H. J., Salisbury S. A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81–83. doi: 10.1038/289081a0. [DOI] [PubMed] [Google Scholar]
  27. Disler R. S., Dover J. S. Chronic localized herpes zoster in the acquired immunodeficiency syndrome. Arch Dermatol. 1990 Aug;126(8):1105–1106. [PubMed] [Google Scholar]
  28. Drew W. L. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. J Acquir Immune Defic Syndr. 1991;4 (Suppl 1):S42–S46. [PubMed] [Google Scholar]
  29. Drew W. L. Cytomegalovirus infection in patients with AIDS. J Infect Dis. 1988 Aug;158(2):449–456. doi: 10.1093/infdis/158.2.449. [DOI] [PubMed] [Google Scholar]
  30. Drew W. L., Miner R. C., Busch D. F., Follansbee S. E., Gullett J., Mehalko S. G., Gordon S. M., Owen W. F., Jr, Matthews T. R., Buhles W. C. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991 Apr;163(4):716–719. doi: 10.1093/infdis/163.4.716. [DOI] [PubMed] [Google Scholar]
  31. Drew W. L. Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patients. Clin Microbiol Rev. 1992 Apr;5(2):204–210. doi: 10.1128/cmr.5.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Drew W. L., Sweet E. S., Miner R. C., Mocarski E. S. Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: documentation by Southern blot hybridization. J Infect Dis. 1984 Dec;150(6):952–953. doi: 10.1093/infdis/150.6.952. [DOI] [PubMed] [Google Scholar]
  33. Drobyski W. R., Knox K. K., Carrigan D. R., Ash R. C. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation. 1991 Jul;52(1):155–157. [PubMed] [Google Scholar]
  34. Dunn D. L., Mayoral J. L., Gillingham K. J., Loeffler C. M., Brayman K. L., Kramer M. A., Erice A., Balfour H. H., Jr, Fletcher C. V., Bolman R. M., 3rd Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation. 1991 Jan;51(1):98–106. doi: 10.1097/00007890-199101000-00015. [DOI] [PubMed] [Google Scholar]
  35. EPSTEIN M. A., ACHONG B. G., BARR Y. M. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet. 1964 Mar 28;1(7335):702–703. doi: 10.1016/s0140-6736(64)91524-7. [DOI] [PubMed] [Google Scholar]
  36. Ebright J. R., Crane L. R. Ganciclovir-resistant cytomegalovirus. AIDS. 1991 May;5(5):604–604. doi: 10.1097/00002030-199105000-00026. [DOI] [PubMed] [Google Scholar]
  37. Ellis M. N., Keller P. M., Fyfe J. A., Martin J. L., Rooney J. F., Straus S. E., Lehrman S. N., Barry D. W. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother. 1987 Jul;31(7):1117–1125. doi: 10.1128/aac.31.7.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ellis M. N., Waters R., Hill E. L., Lobe D. C., Selleseth D. W., Barry D. W. Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1. Antimicrob Agents Chemother. 1989 Mar;33(3):304–310. doi: 10.1128/aac.33.3.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Englund J. A., Zimmerman M. E., Swierkosz E. M., Goodman J. L., Scholl D. R., Balfour H. H., Jr Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med. 1990 Mar 15;112(6):416–422. doi: 10.7326/0003-4819-76-3-112-6-416. [DOI] [PubMed] [Google Scholar]
  40. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jr, Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989 Feb 2;320(5):289–293. doi: 10.1056/NEJM198902023200505. [DOI] [PubMed] [Google Scholar]
  41. Erlich K. S., Mills J., Chatis P., Mertz G. J., Busch D. F., Follansbee S. E., Grant R. M., Crumpacker C. S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):293–296. doi: 10.1056/NEJM198902023200506. [DOI] [PubMed] [Google Scholar]
  42. Farrugia E., Schwab T. R. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc. 1992 Sep;67(9):879–890. doi: 10.1016/s0025-6196(12)60828-3. [DOI] [PubMed] [Google Scholar]
  43. Felsenstein D., D'Amico D. J., Hirsch M. S., Neumeyer D. A., Cederberg D. M., de Miranda P., Schooley R. T. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med. 1985 Sep;103(3):377–380. doi: 10.7326/0003-4819-103-3-377. [DOI] [PubMed] [Google Scholar]
  44. Field A. K., Davies M. E., DeWitt C. M., Perry H. C., Schofield T. L., Karkas J. D., Germershausen J., Wagner A. F., Cantone C. L., MacCoss M. Efficacy of 2'-nor-cyclicGMP in treatment of experimental herpes virus infections. Antiviral Res. 1986 Oct;6(6):329–341. doi: 10.1016/0166-3542(86)90015-x. [DOI] [PubMed] [Google Scholar]
  45. Field H. J., Coen D. M. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol. 1986 Oct;60(1):286–289. doi: 10.1128/jvi.60.1.286-289.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Freifeld A. G., Ostrove J. M. Resistance of viruses to antiviral drugs. Annu Rev Med. 1991;42:247–259. doi: 10.1146/annurev.me.42.020191.001335. [DOI] [PubMed] [Google Scholar]
  47. Friedman-Kien A. E., Lafleur F. L., Gendler E., Hennessey N. P., Montagna R., Halbert S., Rubinstein P., Krasinski K., Zang E., Poiesz B. Herpes zoster: a possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. J Am Acad Dermatol. 1986 Jun;14(6):1023–1028. doi: 10.1016/s0190-9622(86)70127-8. [DOI] [PubMed] [Google Scholar]
  48. Gateley A., Gander R. M., Johnson P. C., Kit S., Otsuka H., Kohl S. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis. 1990 Apr;161(4):711–715. doi: 10.1093/infdis/161.4.711. [DOI] [PubMed] [Google Scholar]
  49. Germershausen J., Bostedor R., Liou R., Field A. K., Wagner A. F., MacCoss M., Tolman R. L., Karkas J. D. Comparison of the modes of antiviral action of 2'-nor-deoxyguanosine and its cyclic phosphate, 2'-nor-cyclic GMP. Antimicrob Agents Chemother. 1986 Jun;29(6):1025–1031. doi: 10.1128/aac.29.6.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Gerna G., Zipeto D., Parea M., Percivalle E., Zavattoni M., Gaballo A., Milanesi G. Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. Mol Cell Probes. 1991 Oct;5(5):365–374. doi: 10.1016/s0890-8508(06)80008-3. [DOI] [PubMed] [Google Scholar]
  51. Gibbs J. S., Chiou H. C., Bastow K. F., Cheng Y. C., Coen D. M. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6672–6676. doi: 10.1073/pnas.85.18.6672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Gibbs J. S., Chiou H. C., Hall J. D., Mount D. W., Retondo M. J., Weller S. K., Coen D. M. Sequence and mapping analyses of the herpes simplex virus DNA polymerase gene predict a C-terminal substrate binding domain. Proc Natl Acad Sci U S A. 1985 Dec;82(23):7969–7973. doi: 10.1073/pnas.82.23.7969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Gilson I. H., Barnett J. H., Conant M. A., Laskin O. L., Williams J., Jones P. G. Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1989 Apr;20(4):637–642. doi: 10.1016/s0190-9622(89)70076-1. [DOI] [PubMed] [Google Scholar]
  54. Goodrich J. M., Bowden R. A., Fisher L., Keller C., Schoch G., Meyers J. D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993 Feb 1;118(3):173–178. doi: 10.7326/0003-4819-118-3-199302010-00003. [DOI] [PubMed] [Google Scholar]
  55. Graham D., Larder B. A., Inglis M. M. Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J Gen Virol. 1986 Apr;67(Pt 4):753–758. doi: 10.1099/0022-1317-67-4-753. [DOI] [PubMed] [Google Scholar]
  56. Gulick R. M., Heath-Chiozzi M., Crumpacker C. S. Varicella-zoster virus disease in patients with human immunodeficiency virus infection. Arch Dermatol. 1990 Aug;126(8):1086–1088. [PubMed] [Google Scholar]
  57. Haffey M. L., Novotny J., Bruccoleri R. E., Carroll R. D., Stevens J. T., Matthews J. T. Structure-function studies of the herpes simplex virus type 1 DNA polymerase. J Virol. 1990 Oct;64(10):5008–5018. doi: 10.1128/jvi.64.10.5008-5018.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Herbst J. S., Morgan J., Raab-Traub N., Resnick L. Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia. J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):753–756. doi: 10.1016/s0190-9622(89)70250-4. [DOI] [PubMed] [Google Scholar]
  59. Hill E. L., Hunter G. A., Ellis M. N. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1991 Nov;35(11):2322–2328. doi: 10.1128/aac.35.11.2322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Hirsch M. S., Schooley R. T. Resistance to antiviral drugs: the end of innocence. N Engl J Med. 1989 Feb 2;320(5):313–314. doi: 10.1056/NEJM198902023200510. [DOI] [PubMed] [Google Scholar]
  61. Hoppenjans W. B., Bibler M. R., Orme R. L., Solinger A. M. Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome. Arch Dermatol. 1990 Aug;126(8):1048–1050. [PubMed] [Google Scholar]
  62. Hwang C. B., Ruffner K. L., Coen D. M. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J Virol. 1992 Mar;66(3):1774–1776. doi: 10.1128/jvi.66.3.1774-1776.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Jacobson M. A., Berger T. G., Fikrig S., Becherer P., Moohr J. W., Stanat S. C., Biron K. K. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Feb 1;112(3):187–191. doi: 10.7326/0003-4819-112-3-187. [DOI] [PubMed] [Google Scholar]
  64. Jacobson M. A., Crowe S., Levy J., Aweeka F., Gambertoglio J., McManus N., Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct;158(4):862–865. [PubMed] [Google Scholar]
  65. Jacobson M. A., Drew W. L., Feinberg J., O'Donnell J. J., Whitmore P. V., Miner R. D., Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis. 1991 Jun;163(6):1348–1351. doi: 10.1093/infdis/163.6.1348. [DOI] [PubMed] [Google Scholar]
  66. Jacobson M. A., Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med. 1988 Apr;108(4):585–594. doi: 10.7326/0003-4819-108-4-585. [DOI] [PubMed] [Google Scholar]
  67. Jacobson M. A., O'Donnell J. J., Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989 May;33(5):736–741. doi: 10.1128/aac.33.5.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Janier M., Hillion B., Baccard M., Morinet F., Scieux C., Perol Y., Civatte J. Chronic varicella zoster infection in acquired immunodeficiency syndrome. J Am Acad Dermatol. 1988 Mar;18(3):584–585. doi: 10.1016/s0190-9622(88)80295-0. [DOI] [PubMed] [Google Scholar]
  69. Jura E., Chadwick E. G., Josephs S. H., Steinberg S. P., Yogev R., Gershon A. A., Krasinski K. M., Borkowsky W. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 1989 Sep;8(9):586–590. doi: 10.1097/00006454-198909000-00003. [DOI] [PubMed] [Google Scholar]
  70. Kaplan M. H., Sadick N., McNutt N. S., Meltzer M., Sarngadharan M. G., Pahwa S. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol. 1987 Mar;16(3 Pt 1):485–506. doi: 10.1016/s0190-9622(87)70066-8. [DOI] [PubMed] [Google Scholar]
  71. Katz B. Z., Raab-Traub N., Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis. 1989 Oct;160(4):589–598. doi: 10.1093/infdis/160.4.589. [DOI] [PubMed] [Google Scholar]
  72. Knox K. K., Drobyski W. R., Carrigan D. R. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet. 1991 May 25;337(8752):1292–1293. doi: 10.1016/0140-6736(91)92965-5. [DOI] [PubMed] [Google Scholar]
  73. Lacey S. F., Suzutani T., Powell K. L., Purifoy D. J., Honess R. W. Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction. J Gen Virol. 1991 Mar;72(Pt 3):623–630. doi: 10.1099/0022-1317-72-3-623. [DOI] [PubMed] [Google Scholar]
  74. Larder B. A., Kemp S. D., Darby G. Related functional domains in virus DNA polymerases. EMBO J. 1987 Jan;6(1):169–175. doi: 10.1002/j.1460-2075.1987.tb04735.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Leibovitz E., Kaul A., Rigaud M., Bebenroth D., Krasinski K., Borkowsky W. Chronic varicella zoster in a child infected with human immunodeficiency virus: case report and review of the literature. Cutis. 1992 Jan;49(1):27–31. [PubMed] [Google Scholar]
  76. Linnemann C. C., Jr, Biron K. K., Hoppenjans W. G., Solinger A. M. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS. 1990 Jun;4(6):577–579. doi: 10.1097/00002030-199006000-00014. [DOI] [PubMed] [Google Scholar]
  77. Littler E., Stuart A. D., Chee M. S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 1992 Jul 9;358(6382):160–162. doi: 10.1038/358160a0. [DOI] [PubMed] [Google Scholar]
  78. Ljungman P., Ellis M. N., Hackman R. C., Shepp D. H., Meyers J. D. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis. 1990 Jul;162(1):244–248. doi: 10.1093/infdis/162.1.244. [DOI] [PubMed] [Google Scholar]
  79. Lurain N. S., Thompson K. D., Holmes E. W., Read G. S. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol. 1992 Dec;66(12):7146–7152. doi: 10.1128/jvi.66.12.7146-7152.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Mar E. C., Chiou J. F., Cheng Y. C., Huang E. S. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Virol. 1985 Mar;53(3):776–780. doi: 10.1128/jvi.53.3.776-780.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Marcy A. I., Hwang C. B., Ruffner K. L., Coen D. M. Engineered herpes simplex virus DNA polymerase point mutants: the most highly conserved region shared among alpha-like DNA polymerases is involved in substrate recognition. J Virol. 1990 Dec;64(12):5883–5890. doi: 10.1128/jvi.64.12.5883-5890.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Marcy A. I., Yager D. R., Coen D. M. Isolation and characterization of herpes simplex virus mutants containing engineered mutations at the DNA polymerase locus. J Virol. 1990 May;64(5):2208–2216. doi: 10.1128/jvi.64.5.2208-2216.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Marks G. L., Nolan P. E., Erlich K. S., Ellis M. N. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis. 1989 May-Jun;11(3):474–476. doi: 10.1093/clinids/11.3.474. [DOI] [PubMed] [Google Scholar]
  84. Matthews J. T., Carroll R. D., Stevens J. T., Haffey M. L. In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme. J Virol. 1989 Nov;63(11):4913–4918. doi: 10.1128/jvi.63.11.4913-4918.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Matthews J. T., Terry B. J., Field A. K. The structure and function of the HSV DNA replication proteins: defining novel antiviral targets. Antiviral Res. 1993 Feb;20(2):89–114. doi: 10.1016/0166-3542(93)90001-y. [DOI] [PubMed] [Google Scholar]
  86. Meyers J. D. Prevention and treatment of cytomegalovirus infection. Annu Rev Med. 1991;42:179–187. doi: 10.1146/annurev.me.42.020191.001143. [DOI] [PubMed] [Google Scholar]
  87. Meyers J. D., Reed E. C., Shepp D. H., Thornquist M., Dandliker P. S., Vicary C. A., Flournoy N., Kirk L. E., Kersey J. H., Thomas E. D. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988 Jan 14;318(2):70–75. doi: 10.1056/NEJM198801143180202. [DOI] [PubMed] [Google Scholar]
  88. Mori H., Shiraki K., Kato T., Hayakawa Y., Yamanishi K., Takahashi M. Molecular analysis of the thymidine kinase gene of thymidine kinase-deficient mutants of varicella-zoster virus. Intervirology. 1988;29(6):301–310. doi: 10.1159/000150060. [DOI] [PubMed] [Google Scholar]
  89. Pagano J. S. Epstein-Barr virus: culprit or consort? N Engl J Med. 1992 Dec 10;327(24):1750–1752. doi: 10.1056/NEJM199212103272410. [DOI] [PubMed] [Google Scholar]
  90. Pahwa S., Biron K., Lim W., Swenson P., Kaplan M. H., Sadick N., Pahwa R. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA. 1988 Nov 18;260(19):2879–2882. [PubMed] [Google Scholar]
  91. Palestine A. G., Polis M. A., De Smet M. D., Baird B. F., Falloon J., Kovacs J. A., Davey R. T., Zurlo J. J., Zunich K. M., Davis M. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991 Nov 1;115(9):665–673. doi: 10.7326/0003-4819-115-9-665. [DOI] [PubMed] [Google Scholar]
  92. Palù G., Gerna G., Bevilacqua F., Marcello A. A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates. Virus Res. 1992 Sep 1;25(1-2):133–144. doi: 10.1016/0168-1702(92)90105-i. [DOI] [PubMed] [Google Scholar]
  93. Parker A. C., Craig J. I., Collins P., Oliver N., Smith I. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase. Lancet. 1987 Dec 19;2(8573):1461–1461. doi: 10.1016/s0140-6736(87)91157-3. [DOI] [PubMed] [Google Scholar]
  94. Parris D. S., Harrington J. E. Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother. 1982 Jul;22(1):71–77. doi: 10.1128/aac.22.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Pau A. K., Pitrak D. L. Management of cytomegalovirus infection in patients with acquired immunodeficiency syndrome. Clin Pharm. 1990 Aug;9(8):613–631. [PubMed] [Google Scholar]
  96. Peters M., Timm U., Schürmann D., Pohle H. D., Ruf B. Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature. Clin Investig. 1992 May;70(5):456–458. doi: 10.1007/BF00235533. [DOI] [PubMed] [Google Scholar]
  97. Plotkin S. A., Drew W. L., Felsenstein D., Hirsch M. S. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis. 1985 Oct;152(4):833–834. doi: 10.1093/infdis/152.4.833. [DOI] [PubMed] [Google Scholar]
  98. Purves F. C., Roizman B. The UL13 gene of herpes simplex virus 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein alpha 22. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7310–7314. doi: 10.1073/pnas.89.16.7310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Pépin J. M., Simon F., Dazza M. C., Brun-Vézinet F. The clinical significance of in vitro cytomegalovirus susceptibility to antiviral drugs. Res Virol. 1992 Mar-Apr;143(2):126–128. doi: 10.1016/s0923-2516(06)80094-4. [DOI] [PubMed] [Google Scholar]
  100. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol. 1992 Oct;3(5):297–307. [PubMed] [Google Scholar]
  101. Reardon J. E., Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405–7411. [PubMed] [Google Scholar]
  102. Roberts G. B., Fyfe J. A., Gaillard R. K., Short S. A. Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. J Virol. 1991 Dec;65(12):6407–6413. doi: 10.1128/jvi.65.12.6407-6413.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Sacks S. L., Wanklin R. J., Reece D. E., Hicks K. A., Tyler K. L., Coen D. M. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med. 1989 Dec 1;111(11):893–899. doi: 10.7326/0003-4819-111-11-893. [DOI] [PubMed] [Google Scholar]
  104. Safrin S., Berger T. G., Gilson I., Wolfe P. R., Wofsy C. B., Mills J., Biron K. K. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991 Jul 1;115(1):19–21. doi: 10.7326/0003-4819-115-1-19. [DOI] [PubMed] [Google Scholar]
  105. Safrin S., Crumpacker C., Chatis P., Davis R., Hafner R., Rush J., Kessler H. A., Landry B., Mills J. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1991 Aug 22;325(8):551–555. doi: 10.1056/NEJM199108223250805. [DOI] [PubMed] [Google Scholar]
  106. Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. J Acquir Immune Defic Syndr. 1992;5 (Suppl 1):S29–S32. [PubMed] [Google Scholar]
  107. Sandvej K., Krenács L., Hamilton-Dutoit S. J., Rindum J. L., Pindborg J. J., Pallesen G. Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia. Histopathology. 1992 May;20(5):387–395. doi: 10.1111/j.1365-2559.1992.tb01008.x. [DOI] [PubMed] [Google Scholar]
  108. Sawyer M. H., Inchauspe G., Biron K. K., Waters D. J., Straus S. E., Ostrove J. M. Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus. J Gen Virol. 1988 Oct;69(Pt 10):2585–2593. doi: 10.1099/0022-1317-69-10-2585. [DOI] [PubMed] [Google Scholar]
  109. Schmidt G. M., Horak D. A., Niland J. C., Duncan S. R., Forman S. J., Zaia J. A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991 Apr 11;324(15):1005–1011. doi: 10.1056/NEJM199104113241501. [DOI] [PubMed] [Google Scholar]
  110. Shepp D. H., Dandliker P. S., Meyers J. D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med. 1986 Jan 23;314(4):208–212. doi: 10.1056/NEJM198601233140404. [DOI] [PubMed] [Google Scholar]
  111. Shepp D. H., Dandliker P. S., de Miranda P., Burnette T. C., Cederberg D. M., Kirk L. E., Meyers J. D. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985 Sep;103(3):368–373. doi: 10.7326/0003-4819-103-3-368. [DOI] [PubMed] [Google Scholar]
  112. Shiraki K., Ogino T., Yamanishi K., Takahashi M. Thymidine kinase with altered substrate specificity of acyclovir resistant varicella-zoster virus. Biken J. 1986 Mar;29(1):7–10. [PubMed] [Google Scholar]
  113. Smith K. J., Kahlter D. C., Davis C., James W. D., Skelton H. G., Angritt P. Acyclovir-resistant varicella zoster responsive to foscarnet. Arch Dermatol. 1991 Jul;127(7):1069–1071. [PubMed] [Google Scholar]
  114. Stanat S. C., Reardon J. E., Erice A., Jordan M. C., Drew W. L., Biron K. K. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother. 1991 Nov;35(11):2191–2197. doi: 10.1128/aac.35.11.2191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Sullivan V., Biron K. K., Talarico C., Stanat S. C., Davis M., Pozzi L. M., Coen D. M. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother. 1993 Jan;37(1):19–25. doi: 10.1128/aac.37.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Sullivan V., Coen D. M. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis. 1991 Oct;164(4):781–784. doi: 10.1093/infdis/164.4.781. [DOI] [PubMed] [Google Scholar]
  117. Sullivan V., Talarico C. L., Stanat S. C., Davis M., Coen D. M., Biron K. K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature. 1992 Jul 9;358(6382):162–164. doi: 10.1038/358162a0. [DOI] [PubMed] [Google Scholar]
  118. Talarico C. L., Phelps W. C., Biron K. K. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol. 1993 Feb;67(2):1024–1033. doi: 10.1128/jvi.67.2.1024-1033.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Tatarowicz W. A., Lurain N. S., Thompson K. D. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis. 1992 Oct;166(4):904–907. doi: 10.1093/infdis/166.4.904. [DOI] [PubMed] [Google Scholar]
  120. Tyms A. S., Davis J. M., Jeffries D. J., Meyers J. D. BWB759U, an analogue of acyclovir, inhibits human cytomegalovirus in vitro. Lancet. 1984 Oct 20;2(8408):924–925. doi: 10.1016/s0140-6736(84)90677-9. [DOI] [PubMed] [Google Scholar]
  121. Tyms A. S., Taylor D. L., Parkin J. M. Cytomegalovirus and the acquired immunodeficiency syndrome. J Antimicrob Chemother. 1989 Jan;23 (Suppl A):89–105. doi: 10.1093/jac/23.suppl_a.89. [DOI] [PubMed] [Google Scholar]
  122. Walling D. M., Edmiston S. N., Sixbey J. W., Abdel-Hamid M., Resnick L., Raab-Traub N. Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6560–6564. doi: 10.1073/pnas.89.14.6560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Wang T. S. Eukaryotic DNA polymerases. Annu Rev Biochem. 1991;60:513–552. doi: 10.1146/annurev.bi.60.070191.002501. [DOI] [PubMed] [Google Scholar]
  124. Weller T. H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med. 1971 Jul 22;285(4):203–214. doi: 10.1056/NEJM197107222850406. [DOI] [PubMed] [Google Scholar]
  125. Whitley R. J., Gnann J. W., Jr Acyclovir: a decade later. N Engl J Med. 1992 Sep 10;327(11):782–789. doi: 10.1056/NEJM199209103271108. [DOI] [PubMed] [Google Scholar]
  126. Whitley R. J., Soong S. J., Dolin R., Betts R., Linnemann C., Jr, Alford C. A., Jr Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982 Oct 14;307(16):971–975. doi: 10.1056/NEJM198210143071602. [DOI] [PubMed] [Google Scholar]
  127. Winston D. J., Ho W. G., Bartoni K., Du Mond C., Ebeling D. F., Buhles W. C., Champlin R. E. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993 Feb 1;118(3):179–184. doi: 10.7326/0003-4819-118-3-199302010-00004. [DOI] [PubMed] [Google Scholar]
  128. de Gans J., Tiessens G., Portegies P., Tutuarima J. A., Troost D. Predominance of polymorphonuclear leukocytes in cerebrospinal fluid of AIDS patients with cytomegalovirus polyradiculomyelitis. J Acquir Immune Defic Syndr. 1990;3(12):1155–1158. [PubMed] [Google Scholar]
  129. van der Horst C., Joncas J., Ahronheim G., Gustafson N., Stein G., Gurwith M., Fleisher G., Sullivan J., Sixbey J., Roland S. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis. 1991 Oct;164(4):788–792. doi: 10.1093/infdis/164.4.788. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES